New minimally invasive technology enhances precision in diagnosing lung cancer — the leading cause of cancer deaths in the U.S.
Valhalla, N.Y. (September 23, 2025) – The Westchester Medical Center Health Network (WMCHealth) has taken another bold step in advancing patient care by investing in the Ion Endoluminal System, a cutting-edge robotic-assisted bronchoscopy platform that enables physicians to perform minimally invasive lung biopsies with unprecedented precision.
Lung cancer remains the leading cause of cancer-related deaths in the United States, claiming the lives of more than 356 Americans every day, according to the American Lung Association. With one of the lowest five-year survival rates of any cancer, early detection is vital. Unfortunately, many cancerous lung nodules are not detected until the disease has already advanced.
The new Ion system empowers WMCHealth clinicians to reach nodules located deep within the lung, areas previously difficult to access, and obtain tissue samples for biopsy with enhanced accuracy. Results from a recent meta-analysis show that Ion-assisted biopsies achieve a diagnosis in up to 83% of cases, giving patients and their physicians critical information sooner and allowing treatment to begin earlier.
“Investing in this technology reflects our ongoing commitment to bringing the most advanced tools in medicine to our community,” said Kassem Harris, M.D., Lead of Interventional Pulmonology; Division of Pulmonary, Critical Care, Allergy & Sleep Medicine at WMCHealth.
“With Ion, our patients can receive faster, more accurate diagnoses, which translates into greater peace of mind, more treatment options, and better outcomes.”
Addressing a Critical Need in the Hudson Valley
According to the New York State Department of Health, nearly 14,000 individuals are diagnosed with lung cancer each year. WMCHealth’s Lung Cancer Program is now equipped with the latest technology to support patients facing this serious and often life-threatening disease.
The Ion system uses unique shape-sensing technology to navigate all 18 segments of the lung and collect tissue with precision. Because the procedure is minimally invasive, it may reduce risks for some patients compared to traditional biopsy methods. Depending on the patient’s care pathway, the procedure may be performed by a thoracic surgeon or an interventional pulmonologist at WMCHealth.
Educating and Empowering Patients
Alongside the adoption of Ion, WMCHealth is committed to helping patients and families better understand lung cancer and their care options by offering education and support, including resources on:
- Lung cancer risk and prevalence
- Screening guidelines and the importance of early detection
- Understanding lung nodules and biopsy options
“Knowledge is power,” added Dr. Harris. “By combining cutting-edge technology with patient education, we can reduce uncertainty, provide clarity, and deliver the highest standard of care to our community.”
For Appointments and More Information
To schedule an appointment or learn more about WMCHealth’s Lung Cancer Program and the Ion Robotic-Assisted Bronchoscopy System, please call 914.493.7518 or visit wmchealth.org/service-line/cancer-care/lung-cancer.